The anti-CD19/CD22 Bispecific CAR lentiviruses are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce the ScFv (single-chain variable fragments) of anti-CD19 (clone FMC63) and anti-CD22 (clone m971) linked to a 2nd generation CAR (Chimeric Antigen Receptor) containing CD8 hinge and transmembrane domains, and the 4-1BB and CD3ζ signaling domains.
The lentiviruses were produced from HEK293T cells, concentrated, and resuspended in DMEM.
Biosafety
The lentiviruses are produced with the SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
Applications Range
Ideal as a positive control for anti-CD19/CD22 Bispecific CAR evaluation in T cells
Use in transduction optimization
Use to generate anti-CD19/CD22 Bispecific CAR-T cells for research use only, not for therapeutic purposes
Storage
Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Shipping
-80°C
No Description Available.
No Description Available.
No Description Available.
Reviews of Anti-CD19/CD22 Bispecific CAR Lentivirus (Clones FMC63/m971 ScFv-CD8-4-1BB-CD3zeta)